Method of treating patients with chronic vesiculitis

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particularly to urology, and concerns treatment of patients with chronic vesculitis. For this purpose patient's lower part is daily placed in pressure chamber and sealed, including area of hypogastrium and pelvis. During 15 minutes pressure influence is performed. During first 5 days patient is exposed to influence with reduced pressure -0.10-0.25 kg/cm2. In following 5 days - increased pressure +0.10-0.25 kg/cm2 is alternated with said reduced pressure from 3 to 5 times per session. Simultaneously with pressure influence antibiotic is drop-by-drop introduced intravenously. Additionally oxytocin at dose 5MU is introduced intramuscularly, once per day, every second day.

EFFECT: in short time method provides efficient eradication of pathogenic microflora from seminal vesicles and total recovery of their functions for long time.

1 ex, 1 tbl

 

The present invention relates to medicine, namely to urology, and can be used in the treatment of patients with chronic vesiculitis.

It is known that chronic vesiculitis is characterized by prolonged and relapsing course, leading to decreased performance, poor sexual and reproductive function in most patients.

There is a method of treatment of patients with chronic prostatitis, including in addition to the antibiotic therapy, and the use of various physiotherapeutic means, improves microcirculation in the prostate gland (Boichenko O.A. method for the treatment of patients with chronic prostatitis. patent of Russia №2119187, MCL. 61N 5/06, 61N 1/36, 61N 2/06, Appl. 1994.02.28., publ. 1998.08.27). The known method includes the stimulation of the prostate gland, in addition to which conduct the irradiation laser light flux and the stationary magnetic field. Thus, electrical stimulation is carried out every other day for 15-20 minutes; the irradiation laser light flux daily during radiation power 6-60 mW, also for 15-20 min; stationary magnetic field affect daily for 60 minutes

The disadvantages of this method of treatment should include the fact that each of these factors affects only the prostate gland and has no effect on seed vs iriki. The authors do not describe control laboratory examination of prostate secretion and semen after treatment.

The closest in technical essence to the present invention is a method of treating chronic vesiculitis by conducting comprehensive therapy, including the use of anti-infective drugs, including antibiotics, and carrying out physiotherapy for the pelvic area. Physiotherapy treatment apparatus "Jari", which combines helium-neon laser, operating in striated muscles of the perineum and pelvis, and electrical stimulation. therapeutic effect is achieved by improving arterial blood flow with medicinal forms, and anti-inflammatory effect is due to the laser beams. Comprehensive therapy 2-week courses with an interval of 5-7 days, depending on the time of growth and development of the organism. (Tiktinsky O.L., Mikhailichenko CENTURIES Andrology. - SPb.: Media Press, 1999. - S-121).

The disadvantages of the known methods and similar, should include that in the treatment of chronic prostatitis impact only on the prostate gland and does not take into account the status of the seminal vesicles, infection which remains.

The task of the invention is to develop a method for the treatment of patients with chronic vesiculitis.

- The m result of the proposed method is to increase the effectiveness of treatment due to the eradication of pathogenic organisms from the seminal vesicles and restore their functions.

The technical result is achieved by a method for the treatment of patients with chronic vesiculitis includes the introduction of antibiotics and carrying out physiotherapy for the pelvic area.

Distinctive techniques of the proposed method lies in the fact that during the 10 day course of treatment in a day intramuscularly injected oxytocin in therapeutic dose of 5 IU once a day, i.e. in the course of treatment the patient receives 5 injections.

Distinctive technique proposed method is that daily zonal barbastella area hypogastrium and pelvis with simultaneous intravenous drip of antibiotics acting on the infectious agent.

The difference of the proposed method lies in the fact that in the first 5 days zonal barbastella carried out under reduced pressure(0,10-0,25) kg/cm2and in the next 5 days in AC mode, alternating high blood pressure +(0,10-0,25) kg/cm2and low pressure(0,10-0,25) kg/cm2by repeating the change of pressure from 3 to 5 times per session. Time barbastelle is 15 minutes.

Comparative analysis of the proposed technical solutions and prototype shows that the inventive method differs from known these techniques. These differences allow to draw a conclusion on the conformity of the proposed technical decision which of the criteria of the invention of "novelty."

Searched known in medicine solutions showed that the distinctive features of the proposed method is not found in the known solutions for the treatment of patients with chronic vesiculitis.

The authors of the proposed method is established that oxytocin promotes eradication of infection of the seminal vesicles. Clinical observations authors suggest that the effectiveness of treatment of chronic vesiculitis when using oxytocin in the dose and pattern of administration. The authors do not know the use of oxytocin for eradication of infection of the seminal vesicles.

According to the follow-up examination after 3, 6, 12 and 24 months after treatment were not observed any pathological changes in the prostate secretion, the ejaculate.

Conducting zonal barbastelle in the first 5 days under reduced pressure(0,10-0,25) kg/cm2provides increased concentrations of intravenous antibiotics in the pelvic area due to enhanced blood flow.

Conducting zonal barbastelle in the next 5 days in AC mode, alternating high and low pressure in the same units, promotes the elimination of venous congestion and restores normal blood flow in the pelvis.

Mode, the pressure and the time for compression and decompression set the author of the mi during clinical observations, as the most optimal for obtaining the best results in the treatment of patients with chronic vesiculitis. Conducted by the authors showed that the so-called "effect of the tide" persists for about 24 hours.

The inventive method achieves perceived by the applicant of the technical result, namely improving the effectiveness of treatment due to the eradication of pathogenic organisms from the seminal vesicles and restore their functions. The above can conclude that the technical solutions according to the criterion of "inventive step".

The method constituting the invention, intended for use in health care. The possibility of its fulfillment is confirmed as described in the application techniques and equipment that meet the criteria of the invention "industrial applicability".

The inventive method of treatment of patients with chronic vesiculitis is as follows. During the course of treatment the patient through the day intramuscularly injected oxytocin in therapeutic dose of 5 to ME once a day. Daily for 15 minutes to conduct zonal barbastella area hypogastrium and pelvis.

For each patient parameters barbastelle chosen individually depending on the values of arterial pressure, pulse rate, and the degree of dilatation of makepolo the CSOs venous plexus and the level of compensation, identified during the Valsalva's test.

To implement barbastelle lower part of the body of the patient is placed in a chamber and sealed. During the first 5 days mode of decompression is performed at a pressure parameters -(0,10-0,25) kg/see In the next 5 days barbastella performed in AC mode: +(0,10-0,25) to(0,10-0,25) kg/cm2. During barbastelle the patient intravenously administered antibiotics, which are pre-selected depending on the sensitivity to the microflora of the ejaculate.

The proposed method for the treatment of patients with chronic vesiculitis is illustrated by a specific example.

Patient A., age 37, was on the examination and treatment with a diagnosis of Chronic nonspecific prostatitis. Chronic vesiculitis, a painful form. The patient for 12 years (average 2 times per year) received different treatments regarding the exacerbation of this disease. The last treatment was about 2 months ago. Asked for help because of the progressive deterioration of health, which consists in increasing pain symptom in the perineum and ejaculation, enhancing erectile dysfunction, episode hemospermia.

During examination of the patient conducted: complaints; physical examination; microscopic examination separated urethra, prostate gland secretion; research is on spermiogram; bacteriological sowing ejaculate; transrectal belanova ultrasound examination of the prostate and seminal vesicles. Patients were excluded sexually transmitted diseases. On a scale quantitative assessment of male copulative function (scale µf) (Laurent O., Segal S., Urology and Nephrology, Moscow, 2001. S. 24-27) the patient scored 40 points out of 60, indicating a moderate violation of the copulative function. If the answer to 7, 8, 9 issues of this scale, related to the function of the seminal vesicles, the patient scored 9 points out of 15 that, according to the authors, showed a significant violation of their functions.

According to the CCS - seminal vesicles enlarged, asymmetric (right - 8,6×5.7 cm, left - 5,8×4.5 cm). Secret of the urethra and prostate revealed increased numbers of leukocytes (up to 30-40 in the field of view). In spermatogonia moderate violations - oligoasthenozoospermia, leukocytes to 80-120 in p/s, a viscosity increase of up to 20 mm At sowing ejaculate showed Staphylococcus haemolyticus, Enterococcus faecium, Enterococcus faecalis, Corynebacterium seminale, Micrococcus lylae. Their total titer was 105-106SOME ml. Revealed sensitivity to levofloxacin.

The patient received treatment by the proposed method, which consisted of intramuscular oxytocin 5 IU (1 ml) in a day, No. 5. Zonal barbastella conducted in the following manner and on the ohms. The lower part of the body, including in the area of hypogastrium and pelvis, was placed in a pressure chamber and sealed. From the chamber by a vacuum pump to drain the air pressure from -0,10 kg/cm2. The duration of exposure to negative pressure (decompression) was 15 minutes. In the next 4 days, given the magnitude of blood pressure and subjective condition of the patient, the magnitude of the negative pressure was gradually lowered to -0,25 kg/cm, the exposure time varied from 10 to 15 minutes.

In the next 5 days spent alternating barbastella. However, the duration of decompression ranged from 3 to 5 minutes at a pressure of from -0,10 to -0,25 kg/cm2. Then there was the injection of air at 1.5-3 min to positive pressure from +0.10 to +0.25 kg/cm2.

In one treatment session conducted replace negative and positive pressure from 3 to 5 times depending on the condition of the patient. The temperature in the chamber during the procedure was maintained at 20-25° C. Simultaneously with the conduction of alternating zonal barbastelle the patient received antibiotic therapy, intravenous drip Tavanic (ampoule form of levofloxacin) 1000 mg

After 3 days of treatment the patient disappeared painful symptoms, but remained discomfort during ejaculation. To 7-th day Le is placed completely stopped the pain symptom.

At the end of treatment according to the CCS-diagnosis - seminal vesicles normal size (the right to 3.8×1,4; left - 3,5×1.6 cm). Microscopic examination of the secret of the urethra, prostate, semen defined isolated leukocytes. Seeded ejaculate - Staphylococcus haemolyticus in title 102that regarded as non-pathogenic significance. On a scale UF patient scored 58 points, if the answer to 7, 8, 9 issues - 15 points. Copulative function is regarded as good.

At follow-up at 1, 3, 6, 12 and 24 months, the patient had no complaints, saved good options indicators of prostate secretion, semen, normal sonographic indicators of the size of the seminal vesicles.

At the present time by the present method treated 108 patients with chronic vesiculitis. For comparison was formed by a group of 54 patients receiving conventional treatment (antibiotics given seeding ejaculate, prostate massage, magnetotherapy). All patients excluded sexually transmitted diseases.

At follow-up one month in patients group traditional treatment continued complaints about discomfort during ejaculation, episodes of hemospermia remained elevated number of cells in the prostate secretion (up to 40 p/h) and the ejaculate (up to 80 p/h), while sowing ejaculate was found pathogenic microflora in the titer 0 5SOME. According to the CCS continued changes in the seminal vesicles: asymmetry, increased size. On a scale áf these patients scored 43 points out of 60, and if the answer to 7, 8, 9 questions 9 points out of 15. After examining this group of patients were invited to undergo treatment by the present method.

The treatment by the proposed method were 108 patients.

In this group, pain was docked for 7-10 days. Conducted on day 10 ultrasound diagnosis established restoration of function of the seminal vesicles. According to the follow-up examination after 3, 6, 12 and 24 months after treatment, patients in this group was not observed any pathological changes in the prostate secretion, semen; the assessment of the copulative function on a scale áf not been a reduction of points. CCS signs of inflammation of the seminal vesicles also was not recorded, and after 2 years of observation.

The effectiveness of the treatment in the long term in patients treated by the present method, amounted to 98.1% (106 patients of 108). In 2 patients in remission to track failed because they did not show up for follow-up examination, although after treatment of complaints and pathological changes in laboratory studies have been identified.

Comparative data for the 2 groups of patients are presented in the table.

So about the time, the proposed method allows in a short time to ensure effective eradication of pathogenic organisms from the seminal vesicles. The use of oxytocin in the treatment of vesicles increases effect of eradication of microflora from the seminal vesicles. The proposed method fully restores the function of the seminal vesicles for a long time. The reduction of treatment time and achieving long-term remission significantly improves the quality of life of patients.

The treatment timeComplaintsThe number of leukocytes in the ejaculateThe titer SOMEChanges S. p. PSMNumber of points in UF (total)Number of points in UF (7, 8, 9 GP.)Violations of spermatogoniaThe number of cells in the prostate gland secretion
Patient group121212 1212121212
Before the treatment++120110106105++414089++4040
After 1 month±-807105102+-4357914+-405

A method of treating sick of the chronic vesiculitis, including antibiotics, and carrying out physiotherapy for the pelvic area, characterized in that oxytocin intramuscularly at a dose of ME, once a day, every day, with daily placed in the chamber and seal the lower part of the body of the patient, including in the area of hypogastrium and pelvis, and within 15 minutes perform barbastella: the first 5 days affected by reduced pressure -0,10-0,25) kg/cm, and for the next 5 days alternate high blood pressure +(0,10-0,25) kg/cm and a specified low pressure from 3 to 5 times per session, simultaneously with brewstation intravenously administered antibiotic.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gynecology and concerns managing pain syndrome in vicarious ovarian enlargement following unilateral adnexectomy. It is ensured by determination of ovary volume by ultrasound. If it increases more than 8 cm3, Femoston 1/10 is introduced one tablet a day before physiological mesopause. Therapy is ultrasound-aided every 2 months, 6 months, and thereafter once a year.

EFFECT: invention provides pain management, reduction of ovary volume, thereby reduced risk of stratification and rupture of its wall.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new compounds with general formula I, in which R1 represents hydrogen or a group, which forms a biologically labile ester, R2 represents hydrogen, C1-C4-alkyl or C1-C4-hydroxyalkyl, and R3 represents C1-C4-alkyl; C1-C4-alkoxy-C1-C4-alkyl; C1-C4-hydroxyalkyl, which is optionally substituted with a second hydroxy group and all hydroxy groups of which are optionally esterified with C2-C4-alkanoyl or amino-acid residue; (C0-C4-alkyl)2amino-C1-C6-alkyl; C3-C7-cycloalkyl; C3-C7-cycloalkyl-C1-C4-alkyl; phenyl-C1-C4-alkyl, the phenyl group of which is optionally substituted 1-2 times with C1-C4-alkyl, C1-C4-alkoxy group and/or halogen; naphthyl-C1-C4-alkyl; C3-C6-oxoalkyl; phenylcarbonylmethyl, the phenyl group of which is optionally substituted 1-2 times with C1-C4-alkyl, C1-C4-alkoxy group and/or halogen, or 2-oxoazepanyl, or R2 and R3 together represent C4-C7-alkylene, methylene groups of which are optionally substituted 1-2 times with carbonyl, nitrogen, oxygen and/or sulphur and/or optionally substituted once with a hydroxy group, which is optionally esterified with C2-C4-alkanoyl or amino-acid residue; C1-C4-alkyl; C1-C4-hydroxyalkyl, the hydroxy group of which is optionally esterified with C2-C4-alkanoyl or amino-acid residue; phenyl or benzyl, and R4 represents hydrogen or a group, which forms a biologically labile ester, where R1 and R4 groups are independently chosen from C1-C4-alkyl; C1-C4-alkoxy-C1-C4-alkoxy-C1-C4-alkyl; C3-C7-cycloalkyl; C3-C7-cycloalkyl-C1-C4-alkyl; N,N-di-(C0-C4-alkyl)amino-C1-C6-alkyl; phenyl or phenyl-C1-C4-alkyl, optionally substituted 1 or 2 times in the phenyl ring with halogen, C1-C4-alkyl or C1-C4-alkoxy group or C1-C4-alkylene chain, bonded with two neighbouring carbon atoms; dioxolanylmethyl, optionally substituted in the dioxolane ring with C1-C4-alkyl; C1-C6-alkanoyloxy-C1-C4-alkyl, optionally substituted in the oxy-C1-C4-alkyl group with C1-C4-alkyl; 1-[[(C1-C4-alkyl)carbonyl]oxy]C1-C4-alkyl esters; 1-[[(C4-C7 cycloalkyloxy)carbonyl]oxy]C1-C4-alkyl esters, 2-oxo-1,3-dioxolan-4-yl-C1-C4-alkyl esters, which optionally contain a double bond in the dioxolane ring; 2-oxo-1,3-dioxolan-4-ylmethyl; and to physiologically compatible salts of acids with formula I and/or to physiologically compatible acid-additive salts of formula I compounds. The invention also relates to a pharmaceutical composition, to use of formula I compounds in paragraph 1, to a method of obtaining formula I compounds, as well as to compounds with general formula II.

EFFECT: obtaining new biologically active compounds, with inhibitory activity towards neutral endopeptidase, endothelin converting enzyme and soluble human endopeptidase.

20 cl, 80 ex, 9 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and namely to urology and deals with treatment of benign hyperplasia of prostate gland. For that purpose 70 ml of 1% placenta hydrolyzate with temperature of 37°C is injected into the rectum of the patient lying on his one side with legs bent in hip joints. Then radiation head with a restrictor of Sterzhen -1 device is introduced into the rectum, and ultrasound action with intensity of 0.3±0.05 W/cm is performed in pulse mode. Effective radiation area is 2cm2 ±10%, pulse frequency is 50 Hz. Duration time of daily procedures is 6 minutes; treatment course consists of 8 procedures.

EFFECT: method provides stimulation of local immunogenesis, regeneration and phagocytosis, normalisation of urination, and increase of recurrence-free period.

6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gynaecology and concerns method for recurrent ovarian cyst prevention following cystectomy. Therefor cystectomy is followed by introduction of herbal receptor-corrective agent which is combined with conventional antibacterial and analgesic therapy. The specified agent is Indinole 300 mg once a day from the third postoperative day. Therapeutic course lasts for 3-6 months.

EFFECT: method provides prolonged recurrence-free period without by-effects and contraindications.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, in particular to gynecology, and concerns endometriosis treatments. With this goal glycoprotein is administered to the sick woman, allocated of a follicular liquid of cattle in a dose of 150-600 mg. Depending on degree of expression of an endometriosis from 10 to 30 injections of a preparation are carried out.

EFFECT: depression of risk of relapses, conservation of genital function.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly gynecology and method of functional ovary cyst treatment. Method involves intramuscular injection of polyoxydonium by 3 mg doses 5 times each other day. Simultaneously, 10% mildronate solution by 5 mg per 200 ml of physiological sodium chloride solution is administered intravenously by drop infusion.

EFFECT: correction of metabolic disorders at system and local levels and normalised immune response of organism due to selected regimen of indicated medicine administration, leading to menstrual cycle and fertility recovery without hormonal therapy.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to children and teenage gynecology and concerns regulating therapy of juvenile uterine bleeding (JUB). For this purpose EEG data are estimated during bleeding. If there are no EEG changes non-hormonal regulating therapy is carried out. If diffuse or dysfunctional changes are present, hormonal regulating therapy is carried out.

EFFECT: method based on objective EEG data allows to eliminate use of hormonal therapy in treatment of juvenile uterine bleedings, ensuring therapeutic efficiency with reduction of JUB recurrence frequency.

3 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: description is given of thiomorpholine derivatives of steroids with general formula I . These steroids are characterised by presence of a thiomorpholine fragment, bonded to a C17 steroid skeleton through an alkylene spacer, where R4 and R4' are hydrogen and methyl, under the condition that, both R4 and R4' represent hydrogen at the same time.

EFFECT: invention can be successfully used for stimulating meiosis of human oocyte.

12 cl, 2 ex, 5 tbl, 6 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention is related to the field of medicines, in particular to tetrahydroquinoline derivatives with common formula (I), where Y-X means C(O)-O, C(O)-NH, S(O)2-NH, NHC(O)-NH, NHC(S)-NH, OC(O)-NH; R6 stands for H, (1-6C)alkyl, 1- or 2-adamantyl(1-4C)alkyl, (3-9C)heteroaryl, (3-6C)cycloalkyl, (2-6C)heterocycloalkyl, alkylthio(1-4C)alkyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl (1-4C)alkyl, (2-6C)heterocycloalkyl (1-4C)alkyl, R8, R9 aminocarbonyl (1-4C) alkyl, R8, R8R9-amino (1-4C)alkyl, R8-oxycarbonyl (1-4C)alkyl, R8-oxy (1-4C)alkyl, R8-carbonyl (1-4C)alkyl or phenyl, not necessarily substituted with hydroxy, amino, halogen, nitro, trifluoromethyl, (3-9C)heteroaryl, (1- 4C)alkylcarbonylamino, (1-4C)alkylcarbonyloxy, (3-9C)heteroarylcarbonyloxy, (3-9C)heteroarylsulfonyloxy, (2-6C)heterocycloalkylcarbamoyl or diphenylamino.

EFFECT: modulating activity in respect to FSH receptor.

17 cl, 74 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, to gynecology in particular. It is designated for optimization of venter metriosis patients treatments in clinical trial. For this purpose patients of the reproductive age intake "Skvaakan" in addition to a hormonal medicine. The intake is implemented intramuscularly, 2.0 ml per day during 75 days with septan interruption after each 30 days. This method contributes to reduction of treatment terms, disease backsets, reactivation of reproductive function among the patients of this category.

EFFECT: reduction of treatment terms, disease backsets, reactivation of reproductive function.

3 cl, 2 tbl, 2 ex

FIELD: medicine; gynaecology.

SUBSTANCE: hemostatics and uterotonic agents are parenterally introduced. Previously folded intrauterine rubber balloon catheter with delivery and support in the form of tubular element rounded at distal end with length that is comparable to but not less than total length of uterine cavity and vagina is introduced into cavity of birth canal. Irrigation and drain tubes from elastic shape-holding material are located on external surface of balloon. Length of tubes exceeds length of tubular element for delivery and support of balloon catheter with possibility of exit beyond the limits of birth canal - from vagina. Distal ends of tubes are rounded with openings on the surface for contents outlet and collection. One of tubes is arranged with the possibility of connection with syringe for introduction of hemostatic into uterine cavity, other tubes are connected with reservoir for collection of drained liquid. Tubular element for delivery and support of balloon catheter is connected with reservoir for filling of balloon catheter with sterile liquid, the second tube installed in reservoir above liquid level is connected to manometer, and pump for pressure charging is located at its end. This device is located from entry to vagina to uterus bottom, fixing proximal end of balloon catheter with tubes in entry to vagina. Then sterile physiological solution is pumped into catheter by means of pump until visually controlled bleeding is arrested. After bleeding has been stopped, pressure value is fixed, then pressure changes are registered in filled balloon catheter, at that pressure rise is treated as restoration of uterus contractive activity, afterwards pulled pressure is reduced in successive steps down to fixed value. If pressure value in catheter drops, it is increased up to fixed value. In both cases fixed pressure of bleeding arrest is maintained for at least 30 minutes, reduction is carried out in successive steps by 10 mm of mercury column every 5-10 minutes. Hemostatics are introduced into uterine cavity by irrigation tube in appropriate doses, then all tubes are isolated for the time sufficient for creation of blood clot. If no bleeding takes place through drain tubes in process of stepwise pressure reduction, pressure is dropped, liquid is removed from balloon catheter, and it is withdrawn outside.

EFFECT: fast and efficient arrest of metrorrhagia by coverage of the whole area of possible bleeding and simultaneous additional effect at local hemostasis by introduction of medicines into uterine cavity.

2 cl, 3 dwg, 2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: application [desamino-1, isoleucine-3, arginine-8]-vasopressin is offered. Means surpasses arginine-8-vasotocin in the declared activity and its application can find at hypernatremia.

EFFECT: increase in excretion of salts of sodium by kidney and strengthening of return selective absorption from uriniferous tubules in water-solvent blood.

1 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical composition in the form of the solid medicinal form contains desmopressin in amount of therapeutically active ingredient.

EFFECT: enlarged period of validity of the specified active ingredient in the specified medicinal form.

15 cl, 1 ex, 9 tbl, 6 dwg

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to method of preparation of hard medicinal form of desmopressin or its pharmaceutically acceptable salt, which includes granulation of said desmopressin or its pharmaceutically acceptable salt and at least one excipient selected from cellulose, starch and lactose, or their mixture, in apparatus for granulation in pseudoliquefied layer. Obtained granulate containing said desmopressin is suitable for being pressed into pharmaceutically acceptable tablet.

EFFECT: obtaining stable preparation of desmopressin.

15 cl, 1 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: new analogues 1-deamino-8-D-arginylvassopressin, which have the following general formula: Mpa-Tyr-Phe-X-Y-Cys-Pro-D-Arg-Gly-NH2, where Mpa is the radical of 3-mercaptoproprionic acid with the formula: SH-CH2-CH2-COOH; X is the amino group which includes alanine, asparagines, glutamine, isoleucine, leucine and valine, Y is an amino-acid from the group, which includes glutamine, isoleucine, leucine and valine. Analogues 1-deamino-8-D-argenyle vasopressin, which has the following formula: where Mpa is the radical of 3-mercaptoproprionic acid with the formula: SH-CH2-CH2-COOH; X is the amino group which includes alanine, asparagines, glutamine, isoleucine, leucine and valine, Y is an amino-acid from the group, which includes glutamine, isoleucine, leucine and valine.

EFFECT: products possess increased effectiveness.

14 cl, 6 dwg, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: method involves opening suppuration focus with following pus evacuation, necrectomy and washing with antiseptic solution. Bandage impregnated with antimicrobial ointment on hydrophilic polyethylene oxide base is applied over injured region. The ointment contains 0.2 g of Ciproflaxin, 5 IU of Oxytocin, 19.05 g of polyethylene oxide-1500, 76.2 g of polyethylene oxide-400.

EFFECT: enhanced effectiveness of treatment.

1 dwg, 2 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a pharmaceutical composition as a solid dosed medicinal formulation comprising desmopressin acetate as a therapeutic component in combination with a pharmaceutically acceptable excipient, diluting agent or carrier or their mixture. This pharmaceutical composition consists of pressed granulate and comprises a lubricating substance in the amount from 0.05 to less 0.40 wt.-% of indicated pharmaceutical composition mass. Indicated amount of lubricant provides increasing both pressing rate and strength of prepared tablets simultaneously.

EFFECT: improved and valuable pharmaceutical properties of composition.

35 cl, 2 dwg, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to preparations, methods for their preparing and using in treatment and prophylaxis of diseases. Invention relates to a pharmaceutical medicinal formulation decomposing into mouth for 10 s and prepared by sublimation of a solvent from the composition comprising desmopressin acetate and sugar and gelatin solvent in a solvent. Also, invention proposes a method for preparing this medicinal formulation. Method involves sublimation of a solvent from the composition comprising desmopressin and sugar and gelatin solution wherein this composition for preparing the medicinal formulation is in the solid state. Also, invention relates to using desmopressin acetate for preparing the claimed formulation used in empty delaying, treatment or prophylaxis of irretention, primary nocturnal enuresis, nycturia or diabetes insipidus of the central nervous system origin. Also, invention proposes a package comprising the claimed medicinal formulation and instruction for its using. The claimed medicinal formulation and method for its using provide enhancing the bioavailability of desmopressin.

EFFECT: improved and valuable properties of formulation.

17 cl, 11 ex

FIELD: new pharmaceutical formulation in solid form, containing desmopressin as active ingredient and method for production thereof.

SUBSTANCE: claimed composition contains Desmopressin as active ingredient as well as pharmaceutically acceptable excipient, diluent or carrier or mixture thereof, wherein at least one from abovementioned excipient, diluent and carrier represents lactose disaccharide. Said lactose has particle size from 70 to 500 mum.

EFFECT: increased pressing rate without losses of tablet quality.

19 cl, 1 ex

FIELD: veterinary science.

SUBSTANCE: one should introduce 1000.0 ml ozonized isotonic sodium chloride solution at 2.2 mg dissolved ozone and 25 U oxytocin intravenously for cows on the 1st, 3d and 5th d of puerperal period. The innovation enables to shorten the period of sterility and spermatic expenses necessary for fertilizing recovered animals.

EFFECT: higher efficiency of prophylaxis.

1 dwg, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention refers to the new compounds of formula I in the form of the salt or zwitter-ion, wherein R1 and R3 are independently phenyl, C3-C8 cycloalkyl or thienyl group, R2 is haloid or hydroxyl group; R4 is C1-C8 alkyl substituted with -NR5-CO-R6 or -CO-NR9R10; R5 is hydrogen ; R6 is C1-C8alkyl or C1-C8 alkoxy, each of them is optionally substituted with 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, or R6 is 5-10-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur; R9 is hydrogen or C1-C8alkyl; R10 is C1-C8alkyl, optionally substituted with cyano group, C1-C8 alkoxy group or with 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, or R10 is 5-9-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur. The invention refers also to the pharmaceutic composition, to the application of compound of any of claims 1-5 as well as to the preparation method of compound of formula I of claim 1.

EFFECT: preparation of the new biologically active compounds taking the effect of muscarin receptor M3.

9 cl, 247 ex, 3 tbl

Up!